Home » GW Tests Cannabinoid Epilepsy Drug in Humans
GW Tests Cannabinoid Epilepsy Drug in Humans
GW Pharmaceuticals has begun testing a cannabinoid drug on patients with epilepsy in a Phase I trial after preclinical data showed that its drug GWP42006 showed fewer side effects than traditional antiepileptic drugs.
Pharma Times
Pharma Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May